Data on Novartis’ Afinitor

Data on Novartis’ Afinitor – Analyst Blog

By: Stock Market News & Stocks to Watch from StraightStocks

Posted on January 14, 2013 at 18:02 PM EST

As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size significantly in patients with non-cancerous kidney tumors.

Related Stocks:

AstraZeneca PLC ADS Bayer Aktiengesellschaft American Depositary Shares Johnson & Johnson Novartis AG ADS Pfizer, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates